# Microbiotica

Source: https://onco.cc/companies/microbiotica/  
OnCo record `microbiotica` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Microbiotica makes precisely defined mixtures of gut bacteria as medicines. Its lead product is given alongside immunotherapy to help more melanoma patients respond.

## Summary

Microbiotica is a clinical-stage live biotherapeutic company at Chesterford Research Park, Cambridge, spun out of Trevor Lawley's laboratory at the Wellcome Sanger Institute. Its clinic-led platform profiles patient microbiomes at strain resolution to identify bacteria associated with clinical benefit, then formulates defined consortia. MB097 is a precision microbiome co-therapy for advanced melanoma given with anti-PD-1 therapy; the international phase 1b MELODY-1 trial completed recruitment in September 2025 and positive results were announced in May 2026. MB310 is a defined consortium for ulcerative colitis with positive phase 1b COMPOSER-1 results in February 2026. The company reports GBP 62 million of equity investment to date, including a GBP 50 million Series B in 2022.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Cambridge
- Type: biotech
- Website: https://www.microbiotica.com

## Notes

- Series B investors not named on fetched pages. Founding year not sourced.

## Sources

- Official website: https://www.microbiotica.com
- About (funding and origins): https://microbiotica.com/about/
- Press releases: https://microbiotica.com/press-releases/

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)

---
JSON: https://onco.cc/api/v1/entities/microbiotica.json